Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2014-11-06 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2014-11-06 English
FORM 4 SUBMISSION
Director's Dealing
2014-11-06 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the securities to be registered, indemnification provisions, and references to other filings but does not contain financial statements or earnings data. It is not an annual report, earnings release, or any other financial report type. It is a capital/financing related filing concerning equity incentive plans and stock options. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, supporting this classification with high confidence.
2014-11-05 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common shares by Xenon Pharmaceuticals Inc. It includes information about the offering size, price, underwriting details, use of proceeds, risk factors, business overview, management, financial data, and other disclosures typical of a securities offering prospectus. The presence of underwriting discounts, offering price, and detailed business and financial information indicates this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual report, earnings release, or any other report type but specifically an offering prospectus related to capital raising.
2014-11-05 English
Regulatory Filings 2014
Regulatory Filings
2014-11-05 English
FORM 3 SUBMISSION
Director's Dealing
2014-11-05 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.